<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410161</url>
  </required_header>
  <id_info>
    <org_study_id>2014-389</org_study_id>
    <nct_id>NCT02410161</nct_id>
  </id_info>
  <brief_title>Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma Fatty Acids</brief_title>
  <official_title>Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma n-3 Polyunsaturated Fatty Acids in Young Compared to Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: As the main alternative fuel to glucose for the brain, increased plasma ketones
      could potentially help compensate for brain glucose hypometabolism occurring during aging.
      The precursor long-chain n-3 polyunsaturated fatty acid (PUFA), α-linolenic acid (ALA), is
      normally mostly β-oxidized and so could potentially be used to stimulate ketogenesis in
      humans.

      Objective: To compare the impact of an ALA-rich supplement on the ketogenic response in young
      and older healthy adults.

      Design: Ten young and ten older adults will consume a flaxseed oil supplement providing 2 g/d
      of ALA for 4 weeks. Plasma ketones, free fatty acids, triglycerides, glucose and insulin will
      be measured over 6 h during two metabolic study days, one before and one at the end of the
      supplementation.

      Hypothesis: ALA-rich supplement for 4 weeks will increase ketone production in both groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dietary Supplement: alpha-linolenic acid-rich supplement</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ketone Production</measure>
    <time_frame>After 4 weeks</time_frame>
    <description>Total Ketone (acetoacetate + beta-hydroxybutyrate) concentration in plasma in average during the metabolic study day, measured hourly between 1 and 6h after breakfast</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose</measure>
    <time_frame>After 4 weeks</time_frame>
    <description>Glucose measured in plasma in average during the metabolic study day, measure hourly between 0 and 6 h after breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Triglycerides</measure>
    <time_frame>After 4 weeks</time_frame>
    <description>Triglycerides measured in plasma in average during the metabolic study day, measured hourly between 1 to 6h after breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Free Fatty Acids</measure>
    <time_frame>4 weeks</time_frame>
    <description>Free fatty acids measured in plasma in average during the metabolic study day, measured hourly between 1 to 6h after breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Concentration in Plasma</measure>
    <time_frame>after 4 weeks</time_frame>
    <description>Insulin measured in plasma in average during the metabolic study day, measured hourly between 0 ans 6 h after breakfast</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>4 week ALA treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>alpha-linolenic acid-rich supplement</intervention_name>
    <description>each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
    <arm_group_label>4 week ALA treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged between 18 and 30 or 65 years and more

        Exclusion Criteria:

          -  non smoker

          -  pregnancy or breastfeeding

          -  diabetes or insulin resistance

          -  uncontrolled thyroid disease, hepatic or renal disease

          -  uncontrolled high blood pressure

          -  medical treatment influencing lipid or glucide metabolism

          -  ongoing or past severe drug or alcohol abuse

          -  dementia or psychiatric difficulties or depression

          -  chronic immune condition or inflammation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Cunnane, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <results_first_submitted>September 12, 2017</results_first_submitted>
  <results_first_submitted_qc>February 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2019</results_first_posted>
  <last_update_submitted>February 11, 2019</last_update_submitted>
  <last_update_submitted_qc>February 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ketone</keyword>
  <keyword>α-linolenic acid</keyword>
  <keyword>flaxseed</keyword>
  <keyword>aging</keyword>
  <keyword>β-hydroxybutyrate</keyword>
  <keyword>acetoacetate</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>ketogenesis</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Young Group 4 Week ALA Treatment</title>
          <description>Participants will receive the alpha-linolenic acid-rich supplement (ALA) (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
        </group>
        <group group_id="P2">
          <title>Old Group 4 Week ALA Treatment</title>
          <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Young Group 4 Week ALA Treatment</title>
          <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
        </group>
        <group group_id="B2">
          <title>Old Group 4 Week ALA Treatment</title>
          <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="2.8"/>
                    <measurement group_id="B2" value="73" spread="7"/>
                    <measurement group_id="B3" value="52" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ketone Production</title>
        <description>Total Ketone (acetoacetate + beta-hydroxybutyrate) concentration in plasma in average during the metabolic study day, measured hourly between 1 and 6h after breakfast</description>
        <time_frame>After 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Group 4 Week ALA Treatment</title>
            <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
          </group>
          <group group_id="O2">
            <title>Old Group 4 Week ALA Treatment</title>
            <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
          </group>
        </group_list>
        <measure>
          <title>Ketone Production</title>
          <description>Total Ketone (acetoacetate + beta-hydroxybutyrate) concentration in plasma in average during the metabolic study day, measured hourly between 1 and 6h after breakfast</description>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.71" spread="24"/>
                    <measurement group_id="O2" value="187.48" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose</title>
        <description>Glucose measured in plasma in average during the metabolic study day, measure hourly between 0 and 6 h after breakfast</description>
        <time_frame>After 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Group 4 Week ALA Treatment</title>
            <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
          </group>
          <group group_id="O2">
            <title>Old Group 4 Week ALA Treatment</title>
            <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose</title>
          <description>Glucose measured in plasma in average during the metabolic study day, measure hourly between 0 and 6 h after breakfast</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.75" spread="0.13"/>
                    <measurement group_id="O2" value="5.46" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Triglycerides</title>
        <description>Triglycerides measured in plasma in average during the metabolic study day, measured hourly between 1 to 6h after breakfast</description>
        <time_frame>After 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Group 4 Week ALA Treatment</title>
            <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
          </group>
          <group group_id="O2">
            <title>Old Group 4 Week ALA Treatment</title>
            <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Triglycerides</title>
          <description>Triglycerides measured in plasma in average during the metabolic study day, measured hourly between 1 to 6h after breakfast</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.15"/>
                    <measurement group_id="O2" value="1.81" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Free Fatty Acids</title>
        <description>Free fatty acids measured in plasma in average during the metabolic study day, measured hourly between 1 to 6h after breakfast</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Group 4 Week ALA Treatment</title>
            <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
          </group>
          <group group_id="O2">
            <title>Old Group 4 Week ALA Treatment</title>
            <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Free Fatty Acids</title>
          <description>Free fatty acids measured in plasma in average during the metabolic study day, measured hourly between 1 to 6h after breakfast</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.05"/>
                    <measurement group_id="O2" value="0.55" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Concentration in Plasma</title>
        <description>Insulin measured in plasma in average during the metabolic study day, measured hourly between 0 ans 6 h after breakfast</description>
        <time_frame>after 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Group 4 Week ALA Treatment</title>
            <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
          </group>
          <group group_id="O2">
            <title>Old Group 4 Week ALA Treatment</title>
            <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Concentration in Plasma</title>
          <description>Insulin measured in plasma in average during the metabolic study day, measured hourly between 0 ans 6 h after breakfast</description>
          <units>µIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.48" spread="1.48"/>
                    <measurement group_id="O2" value="14.87" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event were collected during the 4-weeks supplementation of each participant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Young Group 4 Week ALA Treatment</title>
          <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
        </group>
        <group group_id="E2">
          <title>Old Group 4 Week ALA Treatment</title>
          <description>Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
alpha-linolenic acid-rich supplement: each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pr. Stephen Cunnane</name_or_title>
      <organization>Université de Sherbrooke</organization>
      <phone>819-780-2220 ext 45670</phone>
      <email>stephen.cunnane@usherbrooke.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

